Related Experiment Video
Updated: May 30, 2025

Intrauterine Telemetry to Measure Mouse Contractile Pressure In Vivo
Published on: April 6, 2015
Monitoring of inflammatory preterm responses via myometrial cell based multimodal electrophysiological and optical
Haote Han1, Xia Ying2, Qiaoqiao Chen2
1Key Laboratory of Reproductive Genetics (Ministry of Education) and Department of Obstetrics, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China; Department of Chemistry, ZJU-Hangzhou Global Scientific and Technological Innovation Center, School of Medicine, Zhejiang University, Hangzhou, 310058, China.
Abstract:
Preterm birth (PTB) remains a leading cause of neonatal morbidity and mortality, with inflammation-induced PTB posing a significant challenge due to its complex pathophysiology. To address this, we developed an in vitro platform utilizing hTERT-immortalized human myometrial (hTERT-HM) cells integrated with a multielectrode array (MEA) biosensing system and optical calcium imaging. Compared to primary uterine myometrial cells, hTERT-HM cells exhibit superior reproducibility, high scalability, and convenient manipulation, facilitating the consistent and large-scale investigations. This advanced system facilitates simultaneous real-time monitoring of electrophysiological activity and intracellular calcium transient, providing detailed insights into uterine cell behavior during inflammatory PTB. Our study revealed that oxytocin (OT) induces regular contractions in hTERT-HM cells, and the synergistic effect of OT and lipopolysaccharide (LPS) disrupts electrophysiological patterns and calcium signaling, closely mimicking the pathophysiology of inflammation-induced PTB. Meanwhile, magnesium sulfate is validated to effectively suppress OT-induced calcium release and mitigate LPS-triggered irregular electrophysiological signals. By integrating advanced biosensing technologies and advantages of hTERT-HM cells, this platform offers a reliable, reproducible model to investigate the mechanisms of inflammation-driven PTB and further develop targeted therapeutic interventions.

